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Many autoantibodies to cellular constituents are useful 
biomarkers associated with a certain diagnosis or clinical 
manifestations or both. Autoantibodies in polymyositis/
dermatomyositis (PM/DM) have been actively studied in 
recent years, and several myositis-speciﬁ c antibodies 
(MSAs) have been newly described.
In the previous issue of Arthritis Research & Th erapy, 
Muro and colleagues [1] reported a detailed epidemi o-
logic analysis in central Japan on one of the recently 
described MSAs, anti-MDA-5 (melanoma diﬀ erentia-
tion-associated gene 5). Th is autoantibody was originally 
named anti-CADM-140 because of its association with 
clinically amyopathic DM (CADM) and the molecular 
size (approximately 140 kDa) of the target antigen [2]. 
Th e antigen was only recently identiﬁ ed as MDA-5, a 
cytoplasmic viral RNA receptor with RNA helicase activity 
[3]. MDA-5 is a part of anti-viral innate immunity. 
Stimulation of MDA-5 by its ligand induces type I-
interferon (I-IFN) production, and I-IFN also upregulates 
MDA-5. A strong association of anti-MDA-5 with 
CADM accompanying interstitial lung disease (ILD) was 
conﬁ rmed in several independent studies [3,4]. ILD in 
this subset is often rapidly progressive and resistant to 
treatment, making the detection of anti-MDA-5 clinically 
important. Reports on anti-MDA-5 were limited to Japan 
and Korea until recently, when a study in the US 
conﬁ rmed the presence of this speciﬁ city [5].
MDA-5 as a target of autoantibodies in a subset of DM 
makes an attractive story because both viruses and I-IFN 
have been implicated in the pathogenesis of DM. Muro 
and colleagues [1] showed that, in recent years at their 
institute, an increasing prevalence of anti-MDA-5 in a 
subset of patients was more prevalent in small rural 
towns compared with large cities. Furthermore, cluster-
ing of anti-MDA-5-positive cases to certain years and 
geographical areas is documented. In fact, ﬁ ve out of six 
and four out of four patients with anti-MDA-5 in 2002 
and 2010, respectively, were from the two small areas 
along the Kiso River. Th ese clustering patterns are consis-
tent with the role of environmental factors associated with 
a rural community or the river/water system (or both) in 
the development of anti-MDA-5-positive CADM cases.
Among environmental factors in DM, ultraviolet (UV) 
exposure has been considered important since the 
percentage of DM within PM/DM and prevalence of 
anti-Mi-2 antibodies correlate with the UV index of the 
area [6]. In vitro upregulation of a major DM autoantigen, 
Mi-2, by UV exposure supports this idea. However, given 
the history and occupation of the patients, the role of sun 
exposure seems unlikely in this cohort [1]. Seasonal 
diﬀ erence in onset and relapse in PM/DM was reported 
in several studies and is another factor consistent with 
the role of environmental factors; seasonally skewed 
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onset of PM/DM with anti-Jo-1, all anti-aminoacyl tRNA 
synthetases combined, anti-SRP (anti-signal recognition 
particle), and anti-7SL RNA has been reported [7]. Also, 
other studies show a diﬀ erence in prevalence of PM/DM 
in rural versus urban communities but without a clear 
explanation [8]. Others reported an increased prevalence 
of anti-nuclear antibody among rural populations and 
suggested environmental factors such as certain crops, 
animals, or pesticides as potential causes [9]. Th e role of 
the river/water as environmental factors for produc tion 
of anti-nuclear antibody has been considered mainly on 
the basis of pollution by heavy metals and other chemi-
cals, consumption of contaminated ﬁ sh, and diseases 
transmitted via water or water-related insects [10]. 
Whether the river/water plays a critical role in clustering 
in the study [1] remains to be clariﬁ ed.
Large-scale multi-center studies have been a trend in 
recent years and are based on the assumption that 
environmental or minor genetic diﬀ erences within the 
same country do not have signiﬁ cant eﬀ ects. Samples and 
data from diﬀ erent institutes are pooled together; when 
the diﬀ erences in prevalence of autoantibodies or other 
clinical features between institutions are found, they are 
usually interpreted as bias in recruitment or methodo-
logical heterogeneity between institutions. However, in 
other studies, regional diﬀ erences in prevalence or geo-
graphical clustering of patients with PM/DM, sclero-
derma, or systemic lupus erythematosus or in production 
of certain autoantibodies [11,12] have been reported 
without clear explanation. Genetic heterogeneity within 
the same ethnicity, which may signiﬁ cantly aﬀ ect auto-
antibody production pattern, is also well known. Some of 
the samples from this cohort [1] were included in a 
previous multi-center study in Japan, which reports 11% 
prevalence of anti-MDA-5 in DM [13]. In contrast, preva-
lences of anti-MDA-5 in this small cohort are 27% overall, 
as high as 42% in the last 8 years, and 45% in rural areas 
[1]. Th is diﬀ erence seems to be too much to be explained 
on the basis of recruitment bias or methodo logical errors, 
especially when the data show clustering in small areas.
As shown in Muro’s study [1], the diﬀ erence in genetic 
or environmental factors (or both) related to a speciﬁ c 
geographic area should be carefully evaluated. Th is study 
may also oﬀ er clues that are not apparent in the large 
number of pooled samples in multi-center studies and 
that elucidate the patho genesis of speciﬁ c autoimmune 
disease and production of autoantibodies.
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